GLP-1 skin reactions: what FAERS shows

As GLP-1 receptor agonists reach tens of millions of patients for type 2 diabetes and obesity, dermatologists are cataloguing a set of cutaneous side effects that the pivotal trials were not designed to catch in detail. A review published on 3 September 2026 in Clinics in Dermatology by Dina Elgindi and Vesna Petronic-Rosic analysed FDA Adverse Event Reporting System (FAERS) data to map the injection site and skin reactions linked to this drug class^[1]. The picture that emerges is more varied than the prescribing information alone suggests.

What the prescribing information already tells us

Injection site reactions are documented in the approved labelling. For tirzepatide (Mounjaro, Zepbound), the Mounjaro prescribing information reports that injection site reactions occurred in 3.2% of tirzepatide-treated patients across placebo-controlled trials, compared with 0.4% in the placebo groups^[2]. Among patients who developed anti-tirzepatide antibodies, the incidence was higher at 4.6%, versus 0.7% in antibody-negative patients. Alopecia appears in the post-marketing section of the same label, under skin and subcutaneous tissue, without a frequency figure because spontaneous reporting systems do not generate reliable denominators^[2].

The label reaction rates capture what showed up in structured clinical trials. What FAERS adds is breadth: reports from real-world patients, clinicians, and manufacturers submitted after approval, covering patterns that trials either did not capture or were underpowered to detect at low frequencies.

The FAERS picture: injection site reactions

Elgindi and Petronic-Rosic found that injection site reactions are the most commonly reported cutaneous adverse event in FAERS for this class^[1]. These include erythema (redness), pruritus (itching), induration (hardening of tissue under the skin), bruising, and localised swelling. Most are transient and localised to the injection point. Rotating injection sites and injecting at room temperature are the standard mitigation steps described in approved labelling.

A subset of injection site reactions in the FAERS data involves hypersensitivity: urticaria (hives) and angioedema (deeper swelling, sometimes involving the lips or throat). These are low-frequency but clinically significant because they can signal systemic hypersensitivity requiring treatment discontinuation. The class labelling for GLP-1 receptor agonists includes hypersensitivity as a warning, and FAERS signals reinforce that skin manifestations can be the presenting sign^[1].

Beyond the injection site: systemic skin reactions

The more varied part of the FAERS signal involves skin reactions that are not localised to the injection point. Alopecia, particularly diffuse hair shedding consistent with telogen effluvium triggered by rapid weight loss, appears in the data^[1]. Telogen effluvium after significant caloric restriction is a recognised phenomenon; it typically peaks two to four months after the stressor and resolves as body weight stabilises, though the mechanism here may overlap with the pharmacological effect of the drug itself rather than weight loss alone.

Rash patterns, including morbilliform eruptions and urticaria, appear across multiple GLP-1 receptor agonists in the FAERS data. There are also reports of more specific inflammatory presentations: bullous pemphigoid (an autoimmune blistering condition), psoriasis flares, and skin changes consistent with immune activation^[1]. These are rare based on current data, and causality for individual cases is difficult to establish from a reporting system that captures correlation, not causation. For context on the positive dermatologic signals for this class, see our separate coverage of GLP-1 agonists and dermatologic comorbidities.

Alopecia: what the evidence says specifically

Alopecia is the systemic skin adverse event with the most patient visibility given the GLP-1 class's public profile. The Elgindi and Petronic-Rosic review notes that hair loss in this setting most likely reflects telogen effluvium secondary to caloric deficit and rapid weight change, rather than a direct drug effect on hair follicles^[1]. A separate cohort study published in 2026 found a disproportionate reporting signal for non-scarring alopecia in FAERS data for GLP-1 receptor agonists generally, though the authors of that study applied the same caution about spontaneous reporting bias. Hair loss from telogen effluvium is self-limiting in most cases. If shedding persists beyond six months or is accompanied by other symptoms, dermatology evaluation is warranted.

What this is not

FAERS data cannot establish incidence rates or causation. Reports enter the system voluntarily, from patients, clinicians, or manufacturers, and they are not verified for accuracy. High-profile drugs in widespread use generate more reports simply because more people are watching; this creates a numerator without a reliable denominator. The review by Elgindi and Petronic-Rosic is a descriptive signal-mapping exercise, not a controlled study of risk. It tells you which patterns are being reported; it does not tell you how often they occur per thousand patients treated, or whether they occur more often with one agent than another at equivalent doses.

What it does do is give clinicians a more complete vocabulary for discussing skin side effects with patients before they start one of these agents. Injection site reactions, hair shedding in the first months of treatment, and rare hypersensitivity presentations are now part of the counselling landscape for semaglutide, tirzepatide, and the broader GLP-1 class.

Where this lands

Dermatologists and prescribers are not yet working from a unified monitoring protocol for cutaneous adverse events in GLP-1 receptor agonist users. The Elgindi and Petronic-Rosic review is one of the first systematic attempts to use FAERS data to map the landscape for this class specifically on the skin adverse event dimension. The field will need prospective registries and controlled observational studies with adequate comparison groups before incidence estimates become reliable.

If you are on a GLP-1 receptor agonist and notice injection site changes, new rash, or significant hair shedding, report it to your prescriber. This article is for educational purposes and does not replace advice from a qualified healthcare professional.